[1] Jemal A，Bray F，Center MM，et al. Global cancer statistics[J]. CA Cancer J Clin，2011，61(2)：69-90.

[2] Yang Y，Wang H. Perspectives of nanotechnology in minimally invasive therapy of breast cancer[J]. J Healthc Eng，2013，4(1)：67-86.

[3] Tanaka T，Decuzzi P，Cristofanilli M，et al. Nanotechnology for breast cancer therapy[J]. Biomed Microdevices，2009，11(1)：49-63.

[4] Barenholz Y. Doxil(R)-the first FDA-approved nano-drug：lessons learned[J]. J Control Release，2012，160(2)：117-134.

[5] 贾晋斌，韦青燕. 阿霉素脂质体的研究进展[J]. 中国肿瘤， 2011， 20(5)：372-377.

[6] Brigger I，Dubernet C，Couvreur P. Nanoparticles in cancer therapy and diagnosis[J]. Adv Drug Deliv Rev，2002，54(5)：631-651.

[7] Oerlemans C，Bult W，Bos M，et al. Polymeric micelles in anticancer therapy：targeting，imaging and triggered release[J]. Pharm Res， 2010，27(12)：2569-2589.

[8] Senthil KP，Pastoriza-Santos I，Rodriguez-Gonzalez B，et al. High-yield synthesis and optical response of gold nanostars[J]. Nanotechnology， 2008，19(1)：15606.

[9] Heath JR，Davis ME. Nanotechnology and cancer[J]. Annu Rev Med，2008，59(9)：251-265.

[10] 梅  梅，袁守军. 实体瘤的EPR效应及治疗策略[J]. 解放军药学学报，2008(4)：345-346.

[11] Marcucci F，Lefoulon F. Active targeting with particulate drug carriers in tumor therapy：fundamentals and recent progress[J]. Drug Discov Today，2004，9(5)：219-228.

[12] Gref R，Minamitake Y，Peracchia MT，et al. Biodegradable long-circulating polymeric nanospheres[J]. Science，1994，263(5153)： 1600-1603.

[13] Paliwal SR，Paliwal R，Agrawal GP，et al. Liposomal nanomedicine for breast cancer therapy[J]. Nanomedicine (Lond)，2011，6(6)：1085-1100.

[14] Liu Y，Solomon M，Achilefu S. Perspectives and potential applications of nanomedicine in breast and prostate cancer[J]. Med Res Rev，2013， 33(1)：3-32.

[15] Slamon DJ，Godolphin W，Jones LA，et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science， 1989，244(4905)：707-712.

[16] Huang W，Zhang J，Dorn HC，et al. Assembly of bio-nanoparticles for double controlled drug release[J]. PLoS One，2013，8(9)：e74679.

[17] Grobmyer SR，Morse DL，Fletcher B，et al. The promise of nanotechnology for solving clinical problems in breast cancer[J]. J Surg Oncol，2011，103(4)：317-325.

[18] Zhu L，Ma J，Jia N，et al. Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil：preparation，characterization and cytotoxicity studies[J]. Colloids Surf B Biointerfaces，2009，68(1)：1-6.

[19] 王  玉，王东凯，孙  念. pH-敏感型纳米制剂概述[J]. 中国药剂学杂志网络版，2009，7(2)：72-76.

[20] Sanna V，Pala N，Sechi M. Targeted therapy using nanotechnology： focus on cancer[J]. Int J Nanomedicine，2014，9：467-483.

[21] Ghaffar KA，Giddam AK，Zaman M，et al. Liposomes as nanovaccine delivery systems[J]. Curr Top Med Chem，2014，14(9)：1194-1208.

[22] Gregoriadis G，Wills EJ，Swain CP，et al. Drug-carrier potential of liposomes in cancer chemotherapy[J]. Lancet，1974，1(7870)：1313-1316.

[23] Wetzler M，Thomas DA，Wang ES，et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk，2013，13(4)：430-434.

[24] Chang HI，Yeh MK. Clinical development of liposome-based drugs：formulation，characterization，and  therapeutic efficacy[J]. Int J Nanomedicine，2012，7(1)：49-60.

[25] Brown S，Khan DR. The treatment of breast cancer using liposome technology[J]. J Drug Deliv，2012，2012：212965.

[26] Gabizon A，Shmeeda H，Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin：review of animal and human studies[J]. Clin Pharmacokinet，2003，42(5)：419-436.

[27] Laginha KM，Verwoert S，Charrois GJ，et al. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors[J]. Clin Cancer Res，2005，11(19  Sup 1)：6944-6949.

[28] Yatvin MB，Weinstein JN，Dennis WH，et al. Design of liposomes for enhanced local release of drugs by hyperthermia[J]. Science，1978， 202(4374)：1290-1293.

[29] Kheirolomoom A，Lai CY，Tam SM，et al. Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia[J]. J Control Release，2013， 172 (1)：266-273.

[30] Kullberg M，Owens JL，Mann K. Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes[J]. J Drug Target，2010，18(4)： 313-320.

[31] Huang W，Zhang J，Dorn HC，et al. Assembly of bio-nanoparticles for double controlled drug release[J]. PLoS One，2013，8(9)：e74679.

[32] Schnitzer JE，Oh P. Antibodies to SPARC inhibit albumin binding to SPARC，gp60，and microvascular endothelium[J]. Am J Physiol， 1992，263(6 Pt 2)：1872-1879.

[33] Blanco E，Ferrari M. Emerging nanotherapeutic strategies in breast cancer[J]. Breast，2014，23(1)：10-18.

[34] Bakkialakshmi S，Chandrakala D. A spectroscopic investigations of anticancer drugs binding to bovine serum albumin[J]. Spectrochim Acta A Mol Biomol Spectrosc，2012，88(1)：2-9.

[35] Taheri A，Dinarvand R，Ahadi F，et al. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice[J]. Int J Pharm，2012，431(1/2)：183-189.

[36] Yamamoto Y，Kawano I，Iwase H. Nab-paclitaxel for the treatment of breast cancer：efficacy，safety，and approval[J]. Onco Targets Ther， 2011，4：123-136.

[37] Gradishar WJ，Tjulandin S，Davidson N，et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol，2005，23(31)：7794-7803.

[38] Guan ZZ，Li QL，Feng F，et al. Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer[J]. Asia Pac J Clin Onco，2009，5(3)：165-174.

[39] Chirgwin J，Chua SL. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens：a clinical review[J]. Breast，2011，20(5)：394-406.

[40] Abbasi S，Paul A，Shao W，et al. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer：preparation and in vitro assessment[J]. J Drug Deliv，2012，2012：686108.

[41] 王  生，陆  茵，钱文慧，等. 细胞电荷：抗肿瘤研究潜在的重要靶标[J]. 中国药理学通报，2010，26(12)：1541-1544.

[42] Jithan A，Madhavi K，Madhavi M，et al. Preparation and characterization of albumin nanoparticles encapsulating curcumin  intended for the treatment of breast cancer[J]. Int J Pharm Investig， 2011，1(2)：119-125.

[43] Gradishar WJ，Krasnojon D，Cheporov S，et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer[J]. J Clin Oncol， 2009，27(22)：3611-3619.

[44] 黄  果，蒋序林.  热敏性可降解高分子胶束药物载体的研究进展[J]. 高分子通报，2014，(2)：60-67.

[45] Lee KS，Chung HC，Im SA，et al. Multicenter phase II trial of Genexol-PM，a Cremophor-free，polymeric micelle formulation of paclitaxel，in patients with metastatic breast cancer[J]. Breast Cancer Res Treat，2008，108(2)：241-250.

[46] Burris Iii H，Infante J，Spigel D，et al. A phase I dose-escalation study of NK012[J].  J Clin Oncol，2008，26(15)：25-38.

[47] Hamaguchi T，Doi T，Eguchi-Nakajima T，et al. Phase I study of NK012，a novel SN-38-incorpora ting micellar nanoparticle，in adult patients with solid tumors[J]. Clin Cancer Res，2010，16(20)：5058-5066.

[48] Matsumura Y. Preclinical and clinical studies of NK012，an SN-38-incorporating polymeric micelles，which is designed based on EPR effect[J]. Adv Drug Deliver Rev，2011，63(3)：184-192.

[49] Kutty RV，Feng SS. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers[J]. Biomaterials，2013，34(38)：10160-10171.

[50] Gao ZG，Tian L，Hu J，et al. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles[J]. J Control Release，2011，152(1)：84-89.

[51] Abdel-Rahman MA，Al-Abd AM. Thermoresponsive dendrimers based on oligoethylene glycols：design，synthesis and cytotoxic activity against MCF-7 breast cancer cells[J]. Eur J Med Chem，2013， 69(1)：848-854.

[52] Ueda K，Asai Y，Yoshimura Y，et al. Effect of oil-in-water lipid emulsions prepared with fish oil or soybean oil on the growth of MCF-7 cells and HepG2 cells[J]. J Pharm Pharmacol，2008，60(8)：1069-1075.

[53] Mendes S，Graziani SR，Vitorio TS，et al. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients：a new strategy for neoadjuvant chemotherapy[J]. Gynecol Oncol，2009， 112(2)：400-404.

[54] Galanzha EI，Kim JW，Zharov VP. Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in-vivo detection and killing of circulating cancer stem cells[J]. J Biophotonics， 2009，2(12)：725-735.

[55] Varshosaz J，Sadeghi-Aliabadi H，Ghasemi S，et al. Use of magnetic folate-dextran-retinoic acid micelles for dual targeting of doxorubicin in breast cancer[J].  Biomed Res Int，2013，2013：680712.

[56] 袁  丽，王蓓娣，唐倩倩，等. 介孔二氧化硅纳米粒子应用于可控药物传输系统的若干新进展[J]. 有机化学，2010，30(5)：640-647.

[57] Blanco E，Sangai T，Hsiao A，et al. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment[J]. Cancer Lett，2013，334(2)：245-252.